Does degree of androgen suppression matter in hormone-sensitive prostate cancer?

Journal of Clinical Oncology

Volumn 33, Issue 10, 2015, Pages 1098-1100

  Suzman, Daniel L ^a   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROSTENEDIONE; ANTIANDROGEN; GONADORELIN; GONADORELIN AGONIST; PLACEBO; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; BODY MASS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; EDITORIAL; GLEASON SCORE; HUMAN; LOCAL THERAPY; MALE; METASTASIS; OVERALL SURVIVAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; BLOOD; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROGEN ANTAGONISTS; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TESTOSTERONE;

EID: 84927544573     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.1419     Document Type: Editorial

References (14)

1. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
2. Klotz L, O'Callaghan C, Ding K, et al: Nadir tesosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: A secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 33:1151-1156, 2015
3. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012
4. Ryan CJ, Smith MR, Fizazi K, et al: Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Ann Oncol 25:iv255-iv279, 2014
5. Crook JM, O'Callaghan CJ, Duncan G, et al: Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895-903, 2012
6. Garcia-Albeniz X, Chan JM, Paciorek AT, et al: Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. J Clin Oncol 32, 2014 (suppl 5s; abstr 5003)
7. Taylor LG, Canfield SE, Du XL: Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:2388-2399, 2009
8. Hussain M, Tangen CM, Berry DL, et al: Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-1325, 2013
9. Ryan CJ, Molina A, Li J, et al: Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: Results from an analysis of a randomized phase III trial. J Clin Oncol 31:2791-2798, 2013
10. Oefelein MG, Feng A, Scolieri MJ, et al: Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making. Urology 56:1021-1024, 2000
11. Ross RW, Oh WK, Xie W, et al: Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26:842-847, 2008
12. Yang M, Xie W, Mostaghel E, et al: SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 29:2565-2573, 2011
13. Lawrentschuk N, Fernandes K, Bell D, et al: Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol 185:848-854, 2011
14. Samson DJ, Seidenfeld J, Schmitt B, et al: Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95:361-376, 2002